Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Armesocarb is the enantiopure levorotatory (R)-enantiomer of the psychostimulant mesocarb and serves as its active isomer, being developed as a selective dopamine reuptake inhibitor for central nervous system indications such as Parkinson’s disease and sleep-related disorders. It acts primarily at the dopamine transporter (DAT), where mesocarb derivatives have been characterized as atypical, non-competitive, allosteric inhibitors with high selectivity for DAT over norepinephrine and serotonin transporters, producing wakefulness-promoting and antiparkinsonian effects with reduced amphetamine-like dopaminergic release activity.[1][4][5][9][12]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on armesocarb.